Apoptosis in Alzheimer's disease - An update

Apoptosis

Volumn 5, Issue 1, 2000, Pages 9-16

  Shimohama, Shun ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

amyloid; Aging; Alzheimer's disease; Amyloid precursor protein; Apoptosis; Bcl 2; Caspase; Presenilin; Transcription factor

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CASPASE; CASPASE 2; CASPASE 3; CYCLIN DEPENDENT KINASE 4; CYCLOOXYGENASE 2; DNA FRAGMENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE SYNTHASE; PRESENILIN 1; PRESENILIN 2; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN C JUN; PROTEIN P16; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR;

AGING; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CELL CYCLE; GENE EXPRESSION; GLIA CELL; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NICK END LABELING; PRIORITY JOURNAL; SENILE PLAQUE;

ALZHEIMER DISEASE; APOPTOSIS; BRAIN; BRAIN CHEMISTRY; DNA FRAGMENTATION; HUMANS;

EID: 0034018813     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009625323388     Document Type: Article

References (90)

1. Katzman R. Alzheimer's disease. New Engl J Med 1986; 314: 964-973.
2. Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 1998; 21: 479-505.
3. Masliah E, Terry RD, DeTeresa RM, Hansen LA. Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci Lett 1989; 103: 234-239.
4. Masliah E, Terry RD, Alford M, DeTeresa R, Hansen LA. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am J Pathol 1991; 138: 235-246.
5. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairement. Ann Neurol 1991; 30: 572-580.
6. Barinaga M. Is apoptosi key in Alzheimer's disease? Science 1998; 281: 1303-1304.
7. Su JH, Anderson AJ, Cummings BJ, Cotman CW. Immunohistochemical evidence for apoptosis in Alzheimer's disease. NeuroReport 1994; 5: 2529-2533.
8. Lassmann H, Bancher C, Breitschopf H, et al. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol 1995; 89: 35-41.
9. Smale G, Nichols NR, Brady DR, Finch CE, Horton Jr WE. Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 1995; 133: 225-230.
10. Anderson AJ, Su JH, Cotman CW DNA damage and apoptosis in Alzheimer's disease: Colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J Neurosci 1996; 16: 1710-1719.
11. Troncoso JC, Sukhov RR, Kawas CH, Koliatsos VE. In situ labeling of dying cortical neurons in normal aging and in Alzheimer's disease: correlations with senile plaques and disease progression. J Neuropathol Exp Med 1996; 55: 1134-1142.
12. Charnaut-Marlangue C, Ben-Ari Y. A cautionary note on the use of the TUNEL stain to determine apoptosis. NeuroReport 1995; 7: 61-64.
13. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a caution note. Hepatol 1995; 21: 1465-1468.
14. Savits SI, Rosenbaum DM. Apoptosis in neurological disease. Neurosurgery 1998; 42: 555-574.
15. Perry G, Nunomura A, Smith MA. A suicide note from Alzheimer disease neurons. Nat Med 1998; 4: 897-898.
16. Perry G, Nunomura A. Apoptosis and Alzheimer's disease. Science 1998; 282: 1268.
17. Yuan J, Horvits HR. The Caenorhabditis elegans cell death gene ced-4 encodes a novel protein and is expressed during the period of extensive programmed cell death. Development 1992; 116: 309-320.
18. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvits HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. Cell 1993; 75: 641-652.
19. Hengartner MO, Horvits HR. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian protooncogene bcl-2. Cell 1994; 76: 665-676.
20. Cerretti DP, Kozlosky CJ, Mosley B, et al. Molecular cloning of the interleukin-1-β converting enzyme. Science 1992; 256: 97-100.
21. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4 participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405-413.
22. L, and Apaf-1 form a ternary complex. J Biol Chem 1998; 273: 5841-5845.
23. White E. Life, death, and the pursuit of apoptosis. Genes & Dev 1996; 10: 1-15.
24. Alnemri ES, Livingston DJ, Nicholson DW, et al. Human ICE/CED-3 protease nomenclature. Cell 1996; 87: 171.
25. Hacker G, Vaux DL. A sticky business. Curr Biol 1995; 5: 622-624.
26. Kluck RM, Bossi-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132-1136.
27. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132.
28. Kitamura Y, Shimohama S, Kamoshima W, et al. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res 1998; 780: 260-269.
29. Su JH, Deng G, Cotman CW Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression and brain pathology. J Neuropathol Exp Neurol 1997; 56: 86-93.
30. Tanzi RE. Caspases land on APP: One small step for apoptosis, one giant leap for amyloidosis. Nat Neurosci 1999; 2: 585-586.
31. Kim TW, Pettingel WH, Jung YK, Kovacs DM, Tanzi RE. Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family proteases. Science 1997; 277: 373-376.
32. Barnes NY, Li L, Yoshikawa K, Schwartz LM, Oppenheim RW, Milligan CE. Increased production of amyloid precursor protein provides a substrate for caspase-3 in dying motorneurons. J Neurosci 1998; 18: 5869-5880.
33. Yang X, Chang HY, Baltimore D. Autoproteolytic activation of pro-caspases by oligomerization. Mol Cell 1998; 1: 319-325.
34. Masliah E, Mallory M, Alford M, Tanaka S, Hansen LA. Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. J Neuropatho Exp Neurol 1998; 57: 1041-1052.
35. Krajewski M, Wang H-G, Krajewski S, et al. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (caspase 3), a cell death protease. Cancer Res 1997; 57: 1605-1613.
36. Shimohama S, Tanino H, Fujimoto S. Changes in caspase expression in Alzheimer's disease: Comparison with development and aging. Biochem Biophys Res Commun 1999; 256: 381-384.
37. Burek MJ, Oppenheim RW Programmed cell death in the developing nervous system. Brain Pathol 1996; 6: 427-446.
38. Shimohama S, Fujimoto S, Sumida Y, Tanino H. Differential expression of rat brain Bcl-2 family proteins in development and aging. Biochem Biophys Res Commun 1998; 252: 92-96.
39. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10: 1054-1072.
40. Kitamura Y, Shimohama S, Kamoshima W, Matsuoka Y, Nomura Y, Taniguchi T. Changes of p53 in the brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 1997; 232: 418-421.
41. McShea A, Harris PLR, Webster KR, Wahl AF, Smith MA. Abnormal expression of the cell cycle regulators p16 and CDK4 in Alzheimer's disease. Am J Pathol 1997; 150: 1933-1939.
42. O'Neill LAJ, Kaltschmidt C. NF-κB: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997; 20: 252-258.
43. Herdegen T, Skene P, Bahr M. The c-Jun transcription factor-bipotential mediator of neuronal death, survival and regeneration. Trends Neurosci 1997; 20: 227-231.
44. Yang DD, Kuan C-Y, Whitmarsh AJ, et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 1997; 389: 865-870.
45. Kitamura Y, Shimohama S, Ota T, Matsuoka Y, Nomura Y, Taniguchi T. alteration of transcription factors NF-κB and STAT1 in Alzheimer's disease brains. Neurosci Lett 1997; 237: 17-20.
46. McGeer PL, McGeer EG. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995; 21: 195-218.
47. Smith MA, Harris PLR, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997; 17: 2653-2657.
48. Kitamura Y, Taniguchi T, Shimohama S. Apoptotic cell death in neurons and glial cells: Implications for Alzheimer's disease. Jpn J Pharmacol 1999; 79: 1-5.
49. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998; 87: 319-324.
50. Kitamura Y, Shimohama S, Koike H, et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-γ in Alzheimer's disease brains. Biochem Biophys Res Commun 1999; 254: 582-586.
51. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-1611.
52. Selkoe DJ. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Ann Rev Cell Biol 1994; 10: 373-403.
53. LaFela FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G. The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet 1995; 9: 21-30.
54. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease. J Neurosci 1996; 16: 5795-5811.
55. Zhao B, Chrest FJ, Horton Jr. WE, Sisodia SS, Kusiak JW. Expression of mutant amyloid precursor proteins induces apoptosis in PC12 cells. J Neurosci Res 1997; 47: 253-263.
56. Nishimoto I, Okamoto T, Giambarella U, Iwatsubo T. Apoptosis in neurodegenerative disease. Adv Pharmacol 1997; 41: 337-368.
57. Forloni G, Chiesa R, Smiroldo S, et al. Apoptosis mediated neurotoxicity induced by chronic application of β amyloid fragment 25-35. NeuroReport 1993; 4: 523-526.
58. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 1993; 90: 7951-7955.
59. Gschwind M, Huber G. Apoptotic cell death induced by β-amyloid peptide is cell type dependent. J Neurochem 1995; 65: 292-300.
60. Behl C, Davis J, Klier FG, Schubert D. Amyloid β peptide induces necrosis rather than apoptosis. Brain Res 1994; 645: 253-264.
61. Paradis E, Douillard H, Koutroumanis M, Goodyer C, LeBlanc A. Amyloid β peptide of Alzheimer's disease downregulates Bcl-2 and upregulates Bax expression in human neurons. J Neurosci 1996; 16: 7533-7539.
62. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. β-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992; 12: 376-389.
63. Behl C, Davis J, Cole G, Schubert D. Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem Biophys Res Commun 1992; 186: 944-950.
64. Behl C, Davis J, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 1994; 77: 817-827.
65. Le WD, Colom LV, Wie WJ, Smith RG, Alexianu M, Appel SH. Cell death induced by β-amyloid 1-40 in MES23.5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to apoptosis. Brain Res 1995; 686: 49-60.
66. Rabizadeh S, Bitler CM, Butcher LL, Bredesen DE. Expression of the low affinity nerve growth factor receptor enhances β-amyloid peptide toxicity. Proc Natl Acad Sci USA 1994; 91: 10703-10706.
67. Mattson MP, Guo Q, Furukawa K, Pedersen WA. Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer's disease. J Neurochem 1998; 70: 1-14.
68. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 1996; 17: 1005-1013.
69. Duff K, Eckman C, Zehr C, et al. Increased amyloid-β42 (43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383: 710-713.
70. Scheuner D, Eckman C, Jensen M, et al. The amyloid β protein deposited in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864-870.
71. Tomita T, Maruyama K, Saldo TC, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer's disease (Volga German families) increases the secretion of amyloid β protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA 1997; 94: 2025-2030.
72. Vito P, Wolozin B, Ganjei JK, Iwasaki K, Lacana ED, Adamio L. Requirement of the familial Alzheimer's disease gene PS2 for apoptosis. Opposing effect of ALG-3. J Biol Chem 1996; 271: 31025-31028.
73. Deng G, Pike CJ, Cotman CW Alzheimer-associated presenilin-2 confers increased sensitivity to apoptosis in PC12 cells. FEBS Lett 1996; 397: 50-54.
74. Wolozin B, Iwasaki K, Vito P, et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 1996; 274: 1710-1713.
75. Guo Q, Furukawa K, Sopher BL, et al. Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide. NeuroReport 1996; 8: 379-383.
76. Guo Q, Sopher BL, Pham DG, et al. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid β-peptide: involvement of calcium and oxyradicals. J Neurosci 1997; 17: 4212-4222.
77. Guo Q, Fu W, Sopher BL, et al. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 1999; 5: 101-106.
78. Bursztajn S, DeSouza R, McPhie DL, et al. Overexpression in neurons of human presenilin-1 or a presenilin-1 familial Alzheimer disease mutant does not enhance apoptosis. J Neurosci 1998; 18: 9790-9799.
79. Gervais FG, Xu D, Robertson GS, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-β precursor protein and amyloidogenic Aβ peptide formation. Cell 1999; 97: 395-406.
80. Levitan D, Doyle TG, Brousseau D, et al. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc Natl Acad Sci USA 1996; 93: 14940-14944.
81. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presemlin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864-870.
82. Zhou J, Liyanage U, Medina M, et al. Presenilin 1 interaction in the brain with a novel member of the Armadillo family. NeuroReport 1997; 8: 2085-2090.
83. Murayama M, Tanaka S, Palacino J, et al. Direct association of presenilin-1 with beta-catenin. FEBS Lett 1998; 433: 73-77.
84. Takashima A, Murayama M, Murayama O, et al. Presenilin 1 associates with glycogen synthase kanase-3 beta and its substrate tau. Proc Natl Acad Sci USA 1998; 95: 9637-9641.
85. Yu G, Chen F, Levesque G, et al. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin. J Biol Chem 1998; 273: 16470-16475.
86. Zhang Z, Hartmann H, Do VM, et al. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 1998; 395: 698-702.
87. Nishimura M, Yu G, Levesque G, et al. Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex. Nat Med 1999; 5: 164-169.
88. Weihl CC, Ghadge GD, Kennedy SG, Hay N, Miller RJ, Roos RP. Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB. J Neurosci 1999; 19: 5360-5369.
89. Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997; 275: 661-665.
90. Kennedy SG, Wagner AJ, Conzen SD, et al. The PI3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997; 11: 701-713.